Space 3D printing and the rise of orbital manufacturing biotech
Space 3D printing is the use of additive manufacturing systems in orbit or microgravity environments to produce high‑value components, including biomedical implants, that gain performance or quality benefits unavailable with Earth‑based production. For biotech companies, the promise is straightforward: microgravity reduces gravity‑driven defects like sedimentation, buoyancy, and warping, leading to more uniform structures and better biocompatibility. This is turning orbital manufacturing biotech from a science experiment into a real industrial strategy. By shifting in‑space production of sensitive devices such as microgravity implants, firms can improve consistency while cutting material waste. At the same time, emerging commercial space platforms offer longer‑term access than short‑lived parabolic flights or one‑off missions. Together, these trends explain why investors and researchers now see orbital factories as a future hub for 3D printed medical devices, including the 3D printed retina and other complex tissue‑mimicking structures.
LambdaVision’s 3D printed retina gains quality in microgravity
LambdaVision’s flagship product is a 3D printed retina, built from hundreds of nanoscale layers of bacteriorhodopsin, a light‑activated protein designed to restore sight. On Earth, gravity causes sedimentation and buoyancy in the protein solution, which leads to uneven layering, higher material waste, and fewer usable implants. In orbit, those gravity‑induced defects disappear. Retinas manufactured aboard the International Space Station showed improved uniformity, optical performance, reproducibility, and stability, along with better biocompatibility and reduced raw material consumption. According to LambdaVision, nine ISS missions with Space Tango and more than USD 7.7 million (approx. RM35,420,000) in NASA funding have allowed the team to automate quality control and fault detection to meet regulatory expectations. The company’s tenth ISS investigation shifts focus from process refinement to scaling output, targeting conditions like age‑related macular degeneration and retinitis pigmentosa that affect over 200 million people worldwide.
CosmicMaker turns microgravity printing tests into a space business
Photocentric has spun out CosmicMaker to commercialize its in‑space production technology after a series of parabolic flight tests on Novespace’s Airbus A310 Zero G aircraft. During flights cycling between 0g and 2g, three CosmicMaker printers produced parts from silicon carbide, alumina, and thermoset polymers, with components reported as dimensionally accurate. The microgravity phases delivered a notable surprise: ceramic materials printed better when gravity was absent because heavier particles stayed evenly dispersed rather than settling out of slurry. CosmicMaker’s process keeps printed parts fully surrounded by liquid material, so the developing object remains supported and does not need extra support structures in orbit. Built on Photocentric’s LCD‑based systems that have produced tens of millions of parts on Earth, the platform already handles plastics, ceramics, metals, and composites with low weight and power needs, positioning CosmicMaker as an early provider of flexible space 3D printing systems.
Why microgravity implants can outperform Earth‑made devices
Microgravity implants benefit from a unique physical environment where convection, sedimentation, and buoyancy are largely absent. For protein‑based or particle‑filled systems, this means more even layer formation and consistent particle distribution. LambdaVision’s artificial retina is a clear example: hundreds of bacteriorhodopsin layers can be deposited with greater uniformity, improving optical performance and long‑term stability while reducing waste. In CosmicMaker’s tests, ceramic slurries like silicon carbide and alumina remained well mixed in microgravity, avoiding the density‑driven separation seen during higher‑gravity phases. For biomedical devices, these effects translate into smoother interfaces, fewer internal defects, and potentially better biocompatibility. The lack of gravity‑driven sagging also enables delicate geometries that are hard to print on Earth. Together, these factors make orbital manufacturing biotech attractive for premium medical implants, from 3D printed retina constructs to future microgravity implants in orthopedics, dentistry, and tissue engineering.
From ISS to commercial stations: scaling in‑space production
The International Space Station has served as a vital testbed for space 3D printing and microgravity implants, but its retirement is driving companies to plan for new orbital homes. LambdaVision has already reserved capacity on the upcoming Starlab commercial space station to keep 3D printed retina production running after ISS operations cease. “We’re now thinking about how we scale in orbit and what’s next as we transition from the ISS to other platforms in the future,” said Nicole Wagner, the company’s CEO. CosmicMaker, meanwhile, is preparing for more autonomous printers with centrifugal resin recovery and higher automation so astronauts will not need to oversee every print. As commercial space stations, lunar missions, and orbital depots develop, biotech firms see in‑space production as a competitive advantage, enabling continuous, high‑value manufacturing runs for advanced implants that command premium positioning in future medical markets.
